Identification of type-specific anticancer histone deacetylase inhibitors: road to success
- PMID: 20401613
- DOI: 10.1007/s00280-010-1324-y
Identification of type-specific anticancer histone deacetylase inhibitors: road to success
Abstract
Cancer is a serious and life-eliminating disease. Majority of anticancer agents are non-selective. Along with the cancerous cells they also target the normal ones. An important aspect is to hit the developing mechanism of the tumor, which is highlighted by in silico drug designing. On the basis of novel molecular targets, in silico (computational approach) drug discovery has emerged as today's need. Histone deacetylases are an important therapeutic target for many human cancers. The first and only approved (in 2006) histone deacetylase inhibitors (HDACIs) is Zolinza. Depending on the types of the histone deacetylase (HDAC) enzymes, discovery of type-specific inhibitors is important. With continued research and development, in near future HDACIs are likely to figure prominently in cancer treatment plans. This review presents the overview of HDACs, their role in cancer, their structural classes, activity, catalytic domain and the inhibitors of HDACs for cancer therapy. Also it helps in understanding the open directions in this area of research and highlights the importance of computational approaches in discovering specific drugs for cancer therapy.
Similar articles
-
A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.ChemMedChem. 2010 Apr 6;5(4):591-7. doi: 10.1002/cmdc.200900500. ChemMedChem. 2010. PMID: 20157916
-
Anticancer activities of histone deacetylase inhibitors.Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133. Nat Rev Drug Discov. 2006. PMID: 16955068 Review.
-
Development of histone deacetylase inhibitors for cancer treatment.Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583. Expert Rev Anticancer Ther. 2007. PMID: 17428177 Review.
-
HDAC inhibitors for the treatment of cancer.Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Curr Opin Investig Drugs. 2003. PMID: 14763127 Review.
-
Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.Prog Cell Cycle Res. 2003;5:269-78. Prog Cell Cycle Res. 2003. PMID: 14593721 Review.
Cited by
-
Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.Aging (Albany NY). 2021 May 28;13(11):15336-15352. doi: 10.18632/aging.203091. Epub 2021 May 28. Aging (Albany NY). 2021. PMID: 34047714 Free PMC article.
-
Recent Update of HDAC Inhibitors in Lymphoma.Front Cell Dev Biol. 2020 Sep 3;8:576391. doi: 10.3389/fcell.2020.576391. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33015069 Free PMC article. Review.
-
Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):675-702. doi: 10.1007/s00210-023-02674-4. Epub 2023 Aug 24. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37615708 Review.
-
Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors.Naturwissenschaften. 2011 Oct;98(10):871-87. doi: 10.1007/s00114-011-0839-3. Epub 2011 Sep 4. Naturwissenschaften. 2011. PMID: 21892780
-
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.PLoS One. 2015 Nov 18;10(11):e0143013. doi: 10.1371/journal.pone.0143013. eCollection 2015. PLoS One. 2015. PMID: 26580554 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
